Key Highlights

  • Argent BioPharma shares traded at $0.025, down 13.79%, during the 27 October 2026 trading session.
  • Argent signed a 10-year exclusive worldwide licence over four cannabis genotypes with Thai Phytomed International.
  • Argent will receive a 15% Royalty based on profits from commercialisation.

Shares in Argent BioPharma Ltd (ASX:RGT) were trading at $0.025, down 13.79%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Argent BioPharma is an ASX-listed company focused on pharmaceutical, immune-modulation and anti-inflammatory development. On the same day, the company released an announcement dated 27 October 2026 on the licensing agreement.

Licence Terms (27 October 2026)

In its 27 October 2026 announcement, Argent said the agreement covers four proprietary genotypes (MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2) and gives Thai Phytomed International exclusive worldwide rights to cultivate, process, extract, manufacture, market, distribute, Import and export the genetics and derived products, subject to regulatory requirements. The initial term is 10 years, renewable for a further 10.

The licence is not a sale. The genetics and related intellectual property remain with Argent BioPharma (UK) Ltd, and products such as CannEpil and CimetrA are excluded.

Royalty and Responsibilities

Argent will receive a royalty of 15% of profits from commercialisation, including qualifying sublicensing. Thai Phytomed is responsible for funding commercialisation and for obtaining the cultivation, manufacturing, quality, import and export approvals required in each market.

The company said the transaction supports its strategy of monetising non-core legacy Assets while keeping its internal focus on pharmaceutical development.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Biotechnology and specialty pharmaceutical companies report progress through regulatory meetings, clinical studies, licensing and Capital raisings.

Argent BioPharma shares were trading at $0.025, down 13.79%, against a benchmark gain of 0.49%, a gap of 14.28 percentage points. The figures are session data recorded while the market was open and can change before the market finishes trading.

Risks

The royalty is based on profits, so income depends on the licensee funding and obtaining approvals. The announcement does not state a royalty value or minimum payment.

What Lies Ahead

The announcement points to the licensee’s regulatory approvals and commercialisation steps in each market.

Wrapping Up

Argent shares fell during the session on the day of the licensing announcement. Income from the agreement depends on the licensee’s approvals and profits.